Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) – Pipeline Review, H2 2016’, provides in depth analysis on Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) targeted pipeline therapeutics.

The report provides comprehensive information on the Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10)

The report reviews Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) targeted therapeutics and enlists all their major and minor projects

The report assesses Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC 6.1.1.10) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Crestone Inc

TSRL Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC

6.1.1.10) Overview 5

Therapeutics Development 6

Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC

6.1.1.10) - Products under Development by Stage of Development 6

Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC

6.1.1.10) - Products under Development by Therapy Area 7

Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC

6.1.1.10) - Products under Development by Indication 8

Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC

6.1.1.10) - Pipeline Products Glance 9

Early Stage Products 9

Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC

6.1.1.10) - Products under Development by Companies 10

Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC

6.1.1.10) - Products under Development by Universities/Institutes 12

Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC

6.1.1.10) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 17

Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC

6.1.1.10) - Companies Involved in Therapeutics Development 18

Crestone Inc 18

TSRL Inc 19

Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC

6.1.1.10) - Drug Profiles 20

BXN-112 - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

BXN-113 - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

CRS-3123 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

Small Molecules to Inhibit Methionine tRNA Ligase for Gram Positive Bacterial Infections - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

Small Molecules to Inhibit Methionyl-tRNA Synthetase for Gram Positive Bacterial Infections - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Methionine tRNA Ligase (Methionyl tRNA Synthetase or MARS or EC

6.1.1.10) - Featured News & Press Releases 25

Jul 09, 2014: NIH Launches Phase I Clinical Trial of Novel Drug to Treat Clostridium difficile Infection 25

Appendix 26

Methodology 26

Coverage 26

Secondary Research 26

Primary Research 26

Expert Panel Validation 26

Contact Us 26

Disclaimer 27

List of Tables

List of Tables

Number of Products under Development for, H2 2016 6

Number of Products under Development by Therapy Area, H2 2016 7

Number of Products under Development by Indication, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Products under Investigation by Universities/Institutes, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 15

Number of Products by Stage and Route of Administration, H2 2016 16

Number of Products by Stage and Molecule Type, H2 2016 17

Pipeline by Crestone Inc, H2 2016 18

Pipeline by TSRL Inc, H2 2016 19

List of Figures

List of Figures

Number of Products under Development for, H2 2016 6

Number of Products under Development by Indication, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 9

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Stage and Routes of Administration, H2 2016 16

Number of Products by Stage and Molecule Type, H2 2016 17

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports